Literature DB >> 32817225

Improved Early Detection of Focal Brucellosis Complications with Anti-Brucella IgG.

Nannan Xu1, Xiaomeng Dong1, Yongyuan Yao2, Yanyan Guan3, Fengzhe Chen1, Feng Zheng1, Gang Wang4.   

Abstract

To evaluate the associations of inflammatory factors and serological test results with complicated brucellosis, we recruited 285 patients with a diagnosis of brucellosis between May 2016 and September 2019. The patients were subsequently classified into two groups according to the presence of complications. We collected demographic and clinical information and routine laboratory test results in addition to anti-Brucella IgG and IgM levels. Anti-Brucella IgG and IgM were uniformly tested using enzyme-linked immunosorbent assays (ELISAs) in this study. Among the 285 patients with brucellosis, 111 (38.95%) had complicated brucellosis. Osteoarthritis occurred more often in the subacute and chronic stages than in the acute stage (P = 0.002). Genital infection occurred more frequently in the acute stage than in the other stages (P = 0.023). Fever was not frequently observed in complicated cases (P < 0.001). The erythrocyte sedimentation rate (ESR) and the C-reactive protein (CRP) and anti-Brucella IgM and IgG levels were higher in complicated-brucellosis patients than in uncomplicated-brucellosis patients (P < 0.001). Anti-Brucella IgG, with an area under the curve of 0.885 (95% confidence interval [CI], 0.847 to 0.924), was the most robust indicator of complicated brucellosis. Positive culture, anti-Brucella IgM, the ESR, and CRP could be considered indicators, but their efficacy was weaker than that of IgG. In conclusion, a high ESR, high CRP, high anti-Brucella IgM and IgG levels, and positive culture were indicators of complicated brucellosis; among these, anti-Brucella IgG was the most robust biomarker.
Copyright © 2020 American Society for Microbiology.

Entities:  

Keywords:  Brucella spp; IgG; complicated brucellosis; enzyme-linked immunosorbent assay

Mesh:

Substances:

Year:  2020        PMID: 32817225      PMCID: PMC7512165          DOI: 10.1128/JCM.00903-20

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   11.677


  31 in total

1.  Clinical features and serum profile of inflammatory biomarkers in patients with brucellosis.

Authors:  Jingbo Liu; Xiaotao Zhao
Journal:  J Infect Dev Ctries       Date:  2017-12-10       Impact factor: 0.968

2.  Respiratory system involvement in brucellosis: the results of the Kardelen study.

Authors:  Hakan Erdem; Asuman Inan; Nazif Elaldi; Recep Tekin; Serda Gulsun; Cigdem Ataman-Hatipoglu; Nicholas Beeching; Özcan Deveci; Aysun Yalci; Sibel Bolukcu; Ozgur Dagli
Journal:  Chest       Date:  2014-01       Impact factor: 9.410

Review 3.  Update on brucellosis: therapeutic challenges.

Authors:  Javier Solera
Journal:  Int J Antimicrob Agents       Date:  2010-08-06       Impact factor: 5.283

4.  Brucella endocarditis: clinical, diagnostic, and therapeutic approach.

Authors:  J M Reguera; A Alarcón; F Miralles; J Pachón; C Juárez; J D Colmenero
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-10-18       Impact factor: 3.267

5.  Investigation of human leukocyte antigen in osteoarticular brucellosis

Authors:  Sevim Gönen; Murat Dizbay; Oğuz Söylemezoğlu
Journal:  Turk J Med Sci       Date:  2017-11-13       Impact factor: 0.973

6.  Neurobrucellosis: diagnostic and clinical management of an atypical case.

Authors:  Marco Rossi; Carlo Tascini; Novella Carannante; Giovanni Di Caprio; Sonia Sofia; Carmelo Iacobello
Journal:  New Microbiol       Date:  2018-01-31       Impact factor: 2.479

7.  Predictive Value of Inflammation Markers in Brucellosis.

Authors:  Pinar Sen; Tuna Demirdal; Salih Atakan Nemli
Journal:  Arch Iran Med       Date:  2019-11-01       Impact factor: 1.354

8.  Characteristics of and risk factors for relapse of brucellosis in humans.

Authors:  J Ariza; J Corredoira; R Pallares; P F Viladrich; G Rufi; M Pujol; F Gudiol
Journal:  Clin Infect Dis       Date:  1995-05       Impact factor: 9.079

9.  Clinical features of 2041 human brucellosis cases in China.

Authors:  Yujing Shi; Hui Gao; Georgios Pappas; Qiulan Chen; Mei Li; Jun Xu; Shengjie Lai; Qiaohong Liao; Wenwen Yang; Zhongtao Yi; Zulaguli Rouzi; Hongjie Yu
Journal:  PLoS One       Date:  2018-11-26       Impact factor: 3.240

10.  ELISA is superior to bacterial culture and agglutination test in the diagnosis of brucellosis in an endemic area in China.

Authors:  Nannan Xu; Wei Wang; Fengzhe Chen; Wen Li; Gang Wang
Journal:  BMC Infect Dis       Date:  2020-01-06       Impact factor: 3.090

View more
  5 in total

1.  A systematic analysis of and recommendations for public health events involving brucellosis from 2006 to 2019 in China.

Authors:  Zhiguo Liu; Miao Wang; Yaxin Tian; Zhongqiu Li; Liping Gao; Zhenjun Li
Journal:  Ann Med       Date:  2022-12       Impact factor: 5.348

2.  Short- and long-term follow-up outcomes of patients with Brucella endocarditis: a systematic review of 207 Brucella endocarditis Cases.

Authors:  Xiufeng Li; Tan Wang; Yuanzhi Wang; Songsong Xie; Wenbo Tan; Ping Li
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

3.  Brucellar Knee Arthritis with Knee Joint Tuberculosis: A Case Report and Review of the Literature.

Authors:  Jie Wang; Shuguang Li; Qiang Zhang
Journal:  Infect Drug Resist       Date:  2022-04-08       Impact factor: 4.003

4.  Clinical Features of Human Brucellosis and Risk Factors for Focal Complications: A Retrospective Analysis in a Tertiary-Care Hospital in Beijing, China.

Authors:  Zhili Zhang; Xin Zhang; Xue Chen; Xiao Cui; Miaotian Cai; Liu Yang; Yulin Zhang
Journal:  Int J Gen Med       Date:  2022-09-19

5.  Epidemiological, Clinical and Laboratory Characteristics of Patients with Brucella Infection in Anhui Province, China.

Authors:  Cuixiao Shi; Lianzi Wang; Dongmei Lv; Gang Wang; Hylemariam Mihiretie Mengist; Tengchuan Jin; Bo Wang; Ying Huang; Yajuan Li; Yuanhong Xu
Journal:  Infect Drug Resist       Date:  2021-07-16       Impact factor: 4.003

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.